Redox-Responsive Micellar Nanoparticles from Glycosaminoglycans for CD44 Targeted Drug Delivery

Biomacromolecules
Ana M CarvalhoIva Pashkuleva

Abstract

Cancer progression is associated with overexpression of various receptors at the cell surface. Among these, CD44 is known to recognize and bind specifically hyaluronan (HA) and interact with less affinity to other glycosaminoglycans (GAGs), such as chondroitin sulfate (CS). In this study, we describe a simple method to obtain micellar nanoparticles with a GAG shell (HA or CS) as potential drug delivery systems that target cancer cells overexpressing CD44. Alkanethiol was conjugated at the reducing end of the respective GAG using highly efficient oxime chemistry. The alkane moiety confers amphiphilic behavior to the obtained conjugates and triggers their self-assembly into micellar nanoparticles, while the thiol group adds redox-responsiveness to the system. The properties of the particles depend on the used GAG: HA amphiphiles form more dense, smaller assemblies that are redox sensitive. Both systems allow encapsulation of either hydrophobic or hydrophilic cargos with high efficiency. We demonstrate that the GAGs exposed on the surface of the nanoparticles are with preserved bioactivity and recognized by the cellular receptors: the particles were internalized via CD44 dependent pathways.

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Aug 3, 2005·Nature Reviews. Cancer·Mark M Fuster, Jeffrey D Esko
Oct 26, 2006·Breast Cancer Research : BCR·Carol SheridanHarikrishna Nakshatri
Nov 27, 2009·Journal of Drug Targeting·Giovanna PitarresiGaetano Giammona
Dec 4, 2009·International Journal of Cancer. Journal International Du Cancer·Marzenna WiranowskaAnna Plaas
Dec 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bryan P Toole
Mar 3, 2011·The FEBS Journal·Suniti MisraShibnath Ghatak
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Sep 29, 2011·International Journal of Pharmaceutics·Yanhua LiuZhonggui He
Oct 6, 2011·Molecular Cancer Research : MCR·Jeanne M V Louderbough, Joyce A Schroeder
Mar 21, 2012·Chemical Communications : Chem Comm·Ramon Novoa-Carballal, Axel H E Müller
Mar 31, 2012·Nature·C Glenn Begley, Lee M Ellis
May 15, 2012·Journal of Materials Science. Materials in Medicine·Jing-liang WuZhen-hua Huang
May 21, 2014·Pharmaceutical Research·Shuangshuang SongWeisan Pan
Jul 25, 2014·Chemical Communications : Chem Comm·Jing YuYanglong Hou
Oct 24, 2014·Chemical Communications : Chem Comm·Dhruv ThakarRalf P Richter
Feb 12, 2015·Langmuir : the ACS Journal of Surfaces and Colloids·Indah Nurita KurniasihAndreas Mohr
Aug 2, 2015·Analytica Chimica Acta·Carla SilvaIva Pashkuleva
Aug 19, 2015·Chemical Society Reviews·Biao KangFrederik R Wurm
Sep 2, 2015·Advanced Drug Delivery Reviews·Helena S Azevedo, Iva Pashkuleva
Sep 9, 2015·Nature Biotechnology·Elvin BlancoMauro Ferrari
Oct 11, 2015·Journal of Drug Targeting·George MattheolabakisMansoor M Amiji
Feb 28, 2016·Cancer Letters·Theerawut ChanmeeNaoki Itano
Apr 16, 2016·Soft Matter·Kenneth S Rankin, Daniel Frankel
Jun 11, 2016·Colloids and Surfaces. B, Biointerfaces·Raquel TeixeiraIva Pashkuleva
Feb 23, 2017·Annual Review of Biomedical Engineering·Diana Soares da CostaIva Pashkuleva
Apr 19, 2017·Materials Science & Engineering. C, Materials for Biological Applications·Hongxia LiuJianguo Zhao
Oct 28, 2017·Nature Reviews. Materials·Hongmin ChenXiaoyuan Chen
Jul 14, 2014·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Ramon Novoa-CarballalIva Pashkuleva

❮ Previous
Next ❯

Citations

Jul 6, 2018·Chemistry : a European Journal·Ramon Novoa-CarballalIva Pashkuleva
Oct 23, 2019·Pharmaceutics·Okhil K Nag, James B Delehanty
Dec 2, 2020·Materials Science & Engineering. C, Materials for Biological Applications·Shirin MollazadehMostafa Yazdimamaghani
Oct 23, 2020·Acta Biomaterialia·Ana M CarvalhoIva Pashkuleva
Oct 26, 2021·Advanced Healthcare Materials·Ana M CarvalhoIva Pashkuleva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.